Overview

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Sue O'Dorisio
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Treatments:
Edotreotide
Octreotide
Radiopharmaceuticals
Somatostatin